Progyny, Inc. (NASDAQ:PGNY - Get Free Report) President Michael E. Sturmer sold 4,515 shares of the stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $31.95, for a total transaction of $144,254.25. Following the completion of the transaction, the president now owns 380,038 shares in the company, valued at approximately $12,142,214.10. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.
Progyny Stock Down 0.7 %
NASDAQ PGNY opened at $32.07 on Friday. The firm has a market capitalization of $3.08 billion, a price-to-earnings ratio of 51.73, a PEG ratio of 1.34 and a beta of 1.51. Progyny, Inc. has a 52 week low of $29.44 and a 52 week high of $44.95. The company has a fifty day moving average of $35.35 and a two-hundred day moving average of $35.61.
Progyny (NASDAQ:PGNY - Get Free Report) last released its quarterly earnings results on Tuesday, February 27th. The company reported $0.13 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.09 by $0.04. The business had revenue of $269.94 million for the quarter, compared to analyst estimates of $274.08 million. Progyny had a net margin of 5.70% and a return on equity of 12.64%. The business's revenue for the quarter was up 26.0% on a year-over-year basis. During the same period in the previous year, the company earned $0.03 earnings per share. Equities research analysts anticipate that Progyny, Inc. will post 0.7 EPS for the current year.
Analyst Ratings Changes
POTUS in ‘25 Not Biden/Trump, But
From The Freeport Society | Ad
And I believe when they do take the oath of office, their fingers will be crossed… and America will descend into chaos.
Click here now to see my urgent election warning.
PGNY has been the subject of a number of recent analyst reports. Truist Financial reiterated a "buy" rating and issued a $46.00 price target on shares of Progyny in a research report on Wednesday, April 17th. Leerink Partnrs reiterated an "outperform" rating on shares of Progyny in a research report on Monday, February 26th. KeyCorp lowered their price target on Progyny from $45.00 to $43.00 and set an "overweight" rating on the stock in a report on Wednesday, February 28th. Cantor Fitzgerald restated an "overweight" rating and set a $48.00 price objective on shares of Progyny in a research report on Wednesday, February 28th. Finally, SVB Leerink began coverage on Progyny in a report on Monday, February 26th. They issued an "outperform" rating and a $49.00 target price on the stock. Ten equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of "Buy" and an average price target of $48.30.
Get Our Latest Report on Progyny
Hedge Funds Weigh In On Progyny
Several institutional investors have recently made changes to their positions in the company. RiverPark Advisors LLC boosted its position in Progyny by 54.0% during the fourth quarter. RiverPark Advisors LLC now owns 1,067 shares of the company's stock worth $40,000 after purchasing an additional 374 shares in the last quarter. TFC Financial Management Inc. purchased a new stake in shares of Progyny during the first quarter worth approximately $42,000. Financial Management Professionals Inc. acquired a new stake in Progyny during the 1st quarter worth $52,000. Acadian Asset Management LLC purchased a new position in Progyny in the 3rd quarter worth approximately $53,000. Finally, Parkside Financial Bank & Trust lifted its position in Progyny by 9.3% during the fourth quarter. Parkside Financial Bank & Trust now owns 3,096 shares of the company's stock worth $115,000 after buying an additional 264 shares in the last quarter. 94.93% of the stock is owned by hedge funds and other institutional investors.
Progyny Company Profile
(
Get Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
